In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cellzome licenses Episphere to GlaxoSmithKline

Executive Summary

Less than two years after receiving an option to Cellzome AG's anti-inflammatory kinase inhibitors, GlaxoSmithKline PLC is working with the chemical proteomics company again. This time the Big Pharma has received exclusive rights to Cellzome's Episphere epigenetics platform for development of immuno-inflammation therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies